An Extension Study of V203-AD Study to Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of UB-311
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03531710 |
Recruitment Status :
Terminated
(United Neuroscience has decided to terminate V203-AD-EXT study based on a treatment assignment error)
First Posted : May 22, 2018
Results First Posted : December 17, 2020
Last Update Posted : January 26, 2021
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Alzheimer's Disease | Biological: UB-311 Drug: Placebo | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 34 participants |
Allocation: | Non-Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | An Extension Study of a Phase IIa Study in Patients With Mild Alzheimer's Disease to Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of UBITh® AD Immunotherapeutic Vaccine (UB-311) |
Actual Study Start Date : | August 10, 2018 |
Actual Primary Completion Date : | October 31, 2019 |
Actual Study Completion Date : | October 31, 2019 |

Arm | Intervention/treatment |
---|---|
Experimental: 3 boosters
Subjects will receive 3 doses of UB-311 and 2 doses of placebo.
|
Biological: UB-311
Intramuscular injection Drug: Placebo Intramuscular injection |
Experimental: 3 priming doses followed by 2 boosters
Subjects will receive 5 doses of UB-311.
|
Biological: UB-311
Intramuscular injection |
- The Incidence of Adverse Event (AE)/Serious Adverse Event (SAE) [Safety and Tolerability]). [ Time Frame: Overall Study Duration/Early Termination, over an average study duration of 326 days ]Summary of Treatment Emergent Adverse Events (TEAEs), based on reported adverse events and other safety information including local tolerability at injection site, MRI, vital signs, physical examination, 12-lead ECG and laboratory tests.
- Change From Baseline and Through to the End of the Study in Anti-Aβ Antibody Titers [The Immunogenicity of UB-311] [ Time Frame: Overall Study Duration/Early Termination, over an average study duration of 326 days ]For the immunogenicity assessment of the investigational product, UB-311, the level of anti-Aβ antibodies in the serum samples will be measured by a validated enzyme immunoassay manufactured by United Biomedical, Inc. (UBI). The level of anti-Aβ antibodies is assessed at every visit throughout the study period.
- Change From Baseline and Through to the End of the Study in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog); [ Time Frame: Overall Study Duration/Early Termination, over an average study duration of 326 days ]The ADAS-Cog 13 contains 13 items, with a total scoring range of 0 - 85 and higher scores indicating greater dysfunction. ADAS-Cog scores were evaluated at V1 and V8/ET. The observed values and change from baseline for ADAS-Cog scores by treatment groups in the extension study are presented
- Change From Baseline and Through to the End of the Study in Mini-Mental State Exam (MMSE) [ Time Frame: Overall Study Duration/Early Termination, over an average study duration of 326 days ]The MMSE is a 30-point questionnaire. The total score range is 0 - 30 and lower scores indicating greater impairment. MMSE scores were evaluated at V1 and V8/ET. The observed values and change from baseline for MMSE scores by treatment groups in the extension study are presented
- Change From Baseline and Through to the End of the Study in Clinical Dementia Rating - Sum of Boxes (CDR-SB) [ Time Frame: Overall Study Duration/Early Termination, over an average study duration of 326 days ]The CDR-SB includes 6 domains (0 - 3 points/domain), with a total scoring range of 0 - 18 and higher scores indicate greater impartment. CDR-SB scores were evaluated at V1 and V8/ET. The observed values and change from baseline for CDR-SB scores by treatment groups in the extension study are presented

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 60 Years to 90 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients who participated in V203-AD trial without major safety concerns;
- Stable doses of permitted medications for 3 months before screening;
- With a caregiver;
- Other inclusion criteria apply
Exclusion Criteria:
- Clinically significant neurological disease other than Alzheimer's disease
- Major psychiatric disorder
- Severe systemic disease
- Serious adverse reactions to any vaccine
- Other exclusion criteria apply

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03531710
Taiwan | |
Kaohsiung Chang Gung Memorial Hospital (KS-CGMH) | |
Kaohsiung, Taiwan | |
National Taiwan University Hospital (NTUH) | |
Taipei, Taiwan | |
Taipei Veterans General Hospital (TVGH) | |
Taipei, Taiwan | |
Linkou Chang Gung Memorial Hospital (LK-CGMH) | |
Taoyuan, Taiwan |
Documents provided by United Neuroscience Ltd.:
Responsible Party: | United Neuroscience Ltd. |
ClinicalTrials.gov Identifier: | NCT03531710 |
Other Study ID Numbers: |
V203-AD-EXT |
First Posted: | May 22, 2018 Key Record Dates |
Results First Posted: | December 17, 2020 |
Last Update Posted: | January 26, 2021 |
Last Verified: | January 2021 |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Alzheimer Disease Dementia Brain Diseases Central Nervous System Diseases Nervous System Diseases |
Tauopathies Neurodegenerative Diseases Neurocognitive Disorders Mental Disorders |